Sterling Capital Management LLC Sells 1,379 Shares of IDEXX Laboratories, Inc. $IDXX

Sterling Capital Management LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 35.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,523 shares of the company’s stock after selling 1,379 shares during the period. Sterling Capital Management LLC’s holdings in IDEXX Laboratories were worth $1,317,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Aurora Investment Managers LLC. acquired a new stake in IDEXX Laboratories in the second quarter valued at approximately $2,442,000. National Pension Service increased its holdings in shares of IDEXX Laboratories by 5.6% during the second quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after acquiring an additional 6,885 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of IDEXX Laboratories by 60.9% during the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock worth $8,552,000 after purchasing an additional 5,761 shares during the period. Arizona State Retirement System lifted its holdings in shares of IDEXX Laboratories by 4.9% in the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock worth $11,988,000 after purchasing an additional 1,074 shares in the last quarter. Finally, NEOS Investment Management LLC lifted its holdings in shares of IDEXX Laboratories by 12.5% in the 2nd quarter. NEOS Investment Management LLC now owns 60,354 shares of the company’s stock worth $31,773,000 after purchasing an additional 6,721 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 1.8%

Shares of NASDAQ:IDXX opened at $570.21 on Tuesday. The stock has a market cap of $44.92 billion, a price-to-earnings ratio of 40.10 and a beta of 1.55. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The business’s 50 day moving average is $533.01 and its 200 day moving average is $577.84.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.79% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

IDXX has been the subject of several research reports. Barclays reduced their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Jefferies Financial Group lowered their price objective on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a report on Tuesday, October 20th. Leerink Partners dropped their price objective on shares of IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. UBS Group lifted their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $731.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.